三阴性乳腺癌中的雄激素受体生物学：关于分类为雄激素受体阳性（AR+）或四阴性疾病的依据
Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
作者信息
Barton Valerie N, D'Amato Nicholas C, Gordon Michael A, Christenson Jessica L, Elias Anthony, Richer Jennifer K
机构信息
Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora CO, RC1 North P18-5127 Mail Stop 8104, 12800 E. 19th Ave, Aurora, CO, 80015, USA.
出版信息
Horm Cancer. 2015 Dec;6(5-6):206-13. doi: 10.1007/s12672-015-0232-3. Epub 2015 Jul 23.
Abstract
Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype that lacks estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) amplification. Due to the absence of these receptors, TNBC does not respond to traditional endocrine or HER2-targeted therapies that improve patient prognosis in other breast cancer subtypes. TNBC has a poor prognosis, and currently, there are no effective targeted therapies. Some TNBC tumors express androgen receptor (AR) and may benefit from AR-targeted therapies. Here, we review the literature on AR in TNBC and propose that TNBC be further sub-classified as either AR+ TNBC or quadruple negative breast cancer since targeting AR may represent a viable therapeutic option for a subset of TNBC.
摘要
三阴性乳腺癌（TNBC）是一种侵袭性乳腺癌亚型，缺乏雌激素受体、孕激素受体以及人表皮生长因子受体2（HER2）扩增。由于缺乏这些受体，TNBC对传统内分泌疗法或HER2靶向疗法无反应，而这些疗法可改善其他乳腺癌亚型患者的预后。TNBC预后较差，目前尚无有效的靶向治疗方法。一些TNBC肿瘤表达雄激素受体（AR），可能从AR靶向治疗中获益。在此，我们综述了关于TNBC中AR的文献，并建议将TNBC进一步细分为AR阳性TNBC或四阴性乳腺癌，因为靶向AR可能是一部分TNBC患者可行的治疗选择。
相似文献
1
Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
Horm Cancer. 2015 Dec;6(5-6):206-13. doi: 10.1007/s12672-015-0232-3. Epub 2015 Jul 23.
2
Triple negative breast cancer: special histological types and emerging therapeutic methods.
Cancer Biol Med. 2020 May 15;17(2):293-306. doi: 10.20892/j.issn.2095-3941.2019.0465.
3
Role of the androgen receptor in triple-negative breast cancer.
Clin Adv Hematol Oncol. 2016 Mar;14(3):186-93.
4
Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
Oncologist. 2017 Sep;22(9):1086-1093. doi: 10.1634/theoncologist.2017-0095. Epub 2017 May 30.
5
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
Breast Cancer Res. 2014 Aug 8;16(4):406. doi: 10.1186/s13058-014-0406-x.
6
Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review.
Pharmacol Rev. 2023 Mar;75(2):309-327. doi: 10.1124/pharmrev.122.000665. Epub 2022 Dec 12.
7
Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer.
Horm Cancer. 2018 Apr;9(2):82-94. doi: 10.1007/s12672-017-0314-5. Epub 2018 Jan 16.
8
The Androgen Receptor Promotes Cellular Proliferation by Suppression of G-Protein Coupled Estrogen Receptor Signaling in Triple-Negative Breast Cancer.
Cell Physiol Biochem. 2017;43(5):2047-2061. doi: 10.1159/000484187. Epub 2017 Oct 23.
9
Triple-negative breast cancer molecular subtyping and treatment progress.
Breast Cancer Res. 2020 Jun 9;22(1):61. doi: 10.1186/s13058-020-01296-5.
10
Quadruple-negative breast cancer: novel implications for a new disease.
Breast Cancer Res. 2020 Nov 19;22(1):127. doi: 10.1186/s13058-020-01369-5.
引用本文的文献
1
C/EBPβ increases tumor aggressiveness by enhancing KIFC1 expression in androgen receptor negative triple negative breast cancer.
Cell Commun Signal. 2025 May 30;23(1):255. doi: 10.1186/s12964-025-02243-7.
2
Targeting CDK7 enhances the antitumor efficacy of enzalutamide in androgen receptor-positive triple-negative breast cancer by inhibiting c-MYC-mediated tumorigenesis.
Mol Cancer Ther. 2024 Nov 26. doi: 10.1158/1535-7163.MCT-23-0386.
3
Beyond Triple-Negative: High Prevalence of Quadruple-Negative Breast Cancer in African Americans.
Biomedicines. 2024 Jul 9;12(7):1522. doi: 10.3390/biomedicines12071522.
4
Precise nano-system-based drug delivery and synergistic therapy against androgen receptor-positive triple-negative breast cancer.
Acta Pharm Sin B. 2024 Jun;14(6):2685-2697. doi: 10.1016/j.apsb.2024.03.012. Epub 2024 Mar 14.
5
Treatments Targeting the Androgen Receptor and Its Splice Variants in Breast Cancer.
Int J Mol Sci. 2024 Feb 2;25(3):1817. doi: 10.3390/ijms25031817.
6
Targeting androgen receptor (AR) with a synthetic peptide increases apoptosis in triple negative breast cancer and AR-expressing prostate cancer cell lines.
Cancer Rep (Hoboken). 2024 Jan;7(1):e1922. doi: 10.1002/cnr2.1922. Epub 2023 Oct 30.
7
Core Needle Biopsy Accuracy for Androgen Receptor Expression in Invasive Breast Cancer.
Rev Bras Ginecol Obstet. 2023 Sep;45(9):e535-e541. doi: 10.1055/s-0043-1772486. Epub 2023 Oct 16.
8
Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far.
Onco Targets Ther. 2023 Apr 7;16:235-247. doi: 10.2147/OTT.S379867. eCollection 2023.
9
FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer.
Target Oncol. 2023 Mar;18(2):269-285. doi: 10.1007/s11523-023-00949-7. Epub 2023 Feb 24.
10
Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer.
Cancers (Basel). 2022 Dec 30;15(1):233. doi: 10.3390/cancers15010233.
本文引用的文献
1
Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging.
Angew Chem Int Ed Engl. 2015 Aug 10;54(33):9659-62. doi: 10.1002/anie.201503720. Epub 2015 Jun 17.
2
Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
Oncotarget. 2015 May 30;6(15):12890-908. doi: 10.18632/oncotarget.3849.
3
Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer?
Cancer Treat Rev. 2015 Jun;41(6):547-53. doi: 10.1016/j.ctrv.2015.04.009. Epub 2015 Apr 29.
4
Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.
Breast Cancer Res. 2015 Mar 20;17:43. doi: 10.1186/s13058-015-0550-y.
5
Characterizing Breast Cancer in a Population with Increased Prevalence of Triple-Negative Breast Cancer: Androgen Receptor and ALDH1 Expression in Ghanaian Women.
Ann Surg Oncol. 2015 Nov;22(12):3831-5. doi: 10.1245/s10434-015-4455-x. Epub 2015 Mar 6.
6
Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo.
Mol Cancer Ther. 2015 Mar;14(3):769-78. doi: 10.1158/1535-7163.MCT-14-0926. Epub 2015 Feb 23.
7
Androgen receptor and enzymes in lymph node metastasis and cancer reoccurrence in triple-negative breast cancer.
Int J Biol Markers. 2015 May 26;30(2):e184-9. doi: 10.5301/jbm.5000132.
8
Evaluation of posterolateral lumbar fusion in sheep using mineral scaffolds seeded with cultured bone marrow cells.
Int J Mol Sci. 2014 Dec 16;15(12):23359-76. doi: 10.3390/ijms151223359.
9
L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor.
BMC Cancer. 2014 Dec 15;14:958. doi: 10.1186/1471-2407-14-958.
10
Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
Ann Diagn Pathol. 2015 Feb;19(1):37-42. doi: 10.1016/j.anndiagpath.2014.10.003. Epub 2014 Oct 25.
Zotero 插件